Key US Entresto Barriers Are PA Process & Co-Payments – BMT Poll

Uptake of Novartis AG's heart failure drug Entresto in the US has been slow following approval in July 2015, partly due to the time it has taken to secure insurance coverage, but physicians also complain about other insurance barriers, a new survey by BioMedTracker shows.